Theresa M. Guerin

Theresa M. Guerin

Auto-generated profile, based on publicly available information

Theresa M. Guerin

Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Frederick, MD

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JJJesse Jaynes
Jesse Jaynes
RSRushikesh Sable
Rushikesh Sable
MRMichael Ronzetti
Michael Ronzetti
WBWendy Bautista
Wendy Bautista
ZKZachary Knotts
Zachary Knotts
URUdo Rudloff
Udo Rudloff
Innate defense regulator RP-182 targets CD206 high M2-like macrophages in malignant and noncancerous diseases.

1 January 2008 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Closed access
PDF file
JWJames White
James White
TGTheresa Guerin
Theresa Guerin
HSHollie Swanson
Hollie Swanson
Steven R. PostSteven R. Post
Steven R. Post
HZHaining Zhu
Haining Zhu
ESEric J. Smart
Eric J. Smart
In the current study, we examined whether diabetes affected the ability of HDL to stimulate nitric oxide (NO) production. Using HDL isolated from both diabetic humans and diabetic mouse models, we found that female HDL no longer induced NO synthesis, despite containing equivalent amounts of estrogen as nondiabetic controls. Furthermore, HDL isolated from diabetic females and males prevented acetylcholine-induced stimulation of NO generation. Analyses of both the human and mouse diabetic HDL particles showed that the HDLs contained increased levels of myristic acid. To determine whether myristic acid associated with HDL particles was responsible for the decrease in NO generation, myristic acid was added to HDL isolated from nondiabetic humans and mice. Myristic acid-associated HDL inhibited the generation of NO in a dose-dependent manner. Importantly, diabetic HDL did not alter the levels of endothelial NO synthase or acetylcholine receptors associated with the cells. Surprisingly, diabetic HDL inhibited ionomycin-induced stimulation of NO production without affecting ionomycin-induced increases in intracellular calcium. Further analysis indicated that diabetic HDL prevented calmodulin from interacting with endothelial NO synthase (eNOS) but did not affect the activation of calmodulin kinase or calcium-independent mechanisms for stimulating eNOS. These studies are the first to show that a specific fatty acid associated with HDL inhibits the stimulation of NO generation. These findings have important implications regarding cardiovascular disease in diabetic patients.


3 April 2023
Verified
Other
Open access
BHBrendan Hagerty
Brendan Hagerty
TOT. Norene O'SUllivan
T. Norene O'SUllivan
XZXianyu Zhang
Xianyu Zhang
NCN. Keith Collins
N. Keith Collins
WLWendi Custer Lawrence
Wendi Custer Lawrence
CAChristine Alewine
Christine Alewine
Legends for the three Supplementary Figures.